to trade on say 10x revenue (not earnings but revenue) and given they receive 7% royalty on relenza they GSK would have to sell $429M pa of the stuff...even in the unlikely event they got the orders they could not even go remotely close to filling them mean while tamiflu production is going into overdrive and it is easier to store administer etc...and by then csl will have a vaccine anyway...some analysts reckon bta worth 55c but i cant see how they arrived at such a high figure...its gonna get ugly
- Forums
- ASX - By Stock
- BTA
- psychological reasons
psychological reasons, page-4
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)